A Phase 1/2 interventional study of JL18008 20 μg/kg and Placebo (for 20 μg/kg Group) in HIV Infections, sponsored by Jecho Biopharmaceuticals Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-08-06.
Sponsored by Jecho Biopharmaceuticals Co., Ltd. · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 67 studies in HIV Infections with a site in China — 10 open to participants now, 10 under way, none of them phase 3. HIV Infections · China.
Among the 67 studies in HIV Infections with a site in China, this one is the 42nd largest by planned enrollment of the 50 interventional ones that give a count, is one of 3 that started in 2026, is one of 2 in phase 1/2, and was the 63rd registered.
4,737 studies on the registry are indexed under HIV Infections; 246 are open to participants now.
Browse HIV Infections studies →10 of the 67 studies in HIV Infections with a site in China are open now. Recruiting first, the newest first:
Liaoning Chengda Biotechnology CO., LTD · Sites in China
Ages 18–60
Shanghai Public Health Clinical Center · Sites in China
Ages 18+
Chinese University of Hong Kong · Sites in China
Ages 18+
Affiliated Hospital of Nantong University · Sites in China
Ages 18+
Affiliated Hospital of Guangdong Medical University · Sites in China
Ages 18–60
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
67 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 5 · Phase 3 11 · Phase 4 14
First in 2002; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 80 across 3,491 interventional studies indexed under HIV Infections.
Median enrollment 145 across the 50 interventional studies, 435 across the 16 observational. Of the 33 that completed or were terminated, 8 (24%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 67 have an industry lead sponsor. The 10 most frequent:
Jecho Biopharmaceuticals Co., Ltd. is the lead sponsor of 9 studies on the registry; 6 are open to participants now.
Jecho Biopharmaceuticals Co., Ltd. has 2 studies filed under HIV Infections — fewer than ten, so there is no comparison to draw.
3 of the studies in HIV Infections with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06830668National Center for AIDS/STD Control and Prevention, China CDCSame-Day Restart of B/F/TAF in HIV Patients After NNRTI Discontinuation | 2026-12-31 |
| NCT07579741Jecho Biopharmaceuticals Co., Ltd.A Study to Evaluate JL18008 in Subject With HIV Immunological Non-Responders | 2027-02-12 |
| NCT07932132Liaoning Chengda Biotechnology CO., LTDImmunogenicity and Safety of Freeze-Dried Human Rabies Vaccine (Vero Cell) in Patients Infected With Human Immunodeficiency Virus (HIV) | 2027-06-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 67 studies in HIV Infections with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The Phase Ib clinical trial is an add-on study based on combination antiretroviral therapy (cART). It adopts a multicenter, randomized, double-blind, placebo-controlled, multiple-dose design to evaluate the safety and efficacy of multiple intramuscular injections of JL18008 added to cART in HIV immunological non-responders (INRs).
Based on the Phase Ia clinical data, three dose groups are planned for the Phase Ib trial: 20, 40, and 70 μg/kg of JL18008. Each group is planned to enroll 10 subjects (8 receiving active drug and 2 receiving placebo). All subjects must maintain their original cART regimen unchanged. Subjects in the active treatment groups will receive JL18008 injection in addition to cART, while those in the control group will receive placebo (JL18008 injection buffer) in addition to cART. The dosing regimen is tentatively once weekly (QW) for 4 consecutive weeks, which constitutes one treatment cycle, followed by an observation/follow-up period. The study drug will be administered by intramuscular injection.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Receiving combination antiretroviral therapy (cART) for at least 48 months, with a stable antiretroviral regimen for at least 3 months prior to enrollment.
Maintained -1 RNA below 50 copies/mL for at least 36 months (the earliest test date more than 36 months before enrollment), including transient viral blips (single HIV-1 RNA measurement between 50 and 200 copies/mL after excluding laboratory error). At least two HIV-1 RNA results \<50 copies/mL must be available (one may be from screening).
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive JL18008 20 μg/kg intramuscularly once weekly for 4 weeks, in addition to their stable cART regimen.
Drug: JL18008 20 μg/kg
Participants receive placebo (JL18008 injection buffer) intramuscularly once weekly for 4 weeks, in addition to their stable cART regimen.
Drug: Placebo (for 20 μg/kg Group)
Participants receive JL18008 40 μg/kg intramuscularly once weekly for 4 weeks, in addition to their stable cART regimen.
Drug: JL18008 40 μg/kg
Participants receive placebo (JL18008 injection buffer) intramuscularly once weekly for 4 weeks, in addition to their stable cART regimen.
Drug: Placebo (for 40 μg/kg Group)
Participants receive JL18008 70 μg/kg intramuscularly once weekly for 4 weeks, in addition to their stable cART regimen.
Drug: JL18008 70 μg/kg
Participants receive placebo (JL18008 injection buffer) intramuscularly once weekly for 4 weeks, in addition to their stable cART regimen.
Drug: Placebo (for 70 μg/kg Group)
Participants receive JL18008 20 μg/kg by intramuscular injection once weekly for 4 weeks, in addition to their stable combination antiretroviral therapy (cART).
Participants receive placebo (JL18008 injection buffer) by intramuscular injection once weekly for 4 weeks, in addition to their stable combination antiretroviral therapy (cART).
Participants receive JL18008 40 μg/kg by intramuscular injection once weekly for 4 weeks, in addition to their stable combination antiretroviral therapy (cART).
Participants receive placebo (JL18008 injection buffer) by intramuscular injection once weekly for 4 weeks, in addition to their stable combination antiretroviral therapy (cART).
Participants receive JL18008 70 μg/kg by intramuscular injection once weekly for 4 weeks, in addition to their stable combination antiretroviral therapy (cART).
Participants receive placebo (JL18008 injection buffer) by intramuscular injection once weekly for 4 weeks, in addition to their stable combination antiretroviral therapy (cART).
Number of Participants with Treatment-Emergent Adverse Events (TEAEs) as Assessed by DAIDS v2.1
The incidence and severity of adverse events (AEs) and serious adverse events (SAEs). Adverse events are graded according to the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.1. Assessed from first dose up to Week 24.
Time frame: Up to 24 weeks
Change from Baseline in Vital Signs: Pulse Rate (bpm)
Change from baseline in pulse rate. Measured in beats per minute (bpm). Assessed at baseline and Weeks 1, 4, 8, 12, 16, 20, and 24.
Time frame: Up to 24 weeks
Change from Baseline in Vital Signs: Systolic and Diastolic Blood Pressure (mmHg)
Change from baseline in systolic blood pressure (SBP) and diastolic blood pressure (DBP). Both measured in millimeters of mercury (mmHg). Assessed at baseline and Weeks 1, 4, 8, 12, 16, 20, and 24.
Time frame: Up to 24 weeks
Change from Baseline in Hematology Parameters
Change from baseline in hematology parameters including white blood cell count (10\^9/L), hemoglobin (g/L), platelet count (10\^9/L), neutrophil count (10\^9/L), lymphocyte count (10\^9/L), and red blood cell count (10\^12/L). Assessed at baseline and Weeks 1, 2, 4, 8, 12, 16, 20, and 24.
Time frame: Up to 24 weeks
Change from Baseline in Serum Chemistry Parameters
hange from baseline in serum chemistry parameters including alanine aminotransferase (ALT, U/L), aspartate aminotransferase (AST, U/L), creatinine (μmol/L), triglycerides (mmol/L), total cholesterol (mmol/L), glucose (mmol/L), and electrolytes (Na⁺, K⁺, Cl-, Ca²⁺, Mg²⁺, Pi). Assessed at baseline and Weeks 1, 2, 4, 8, 12, 16, 20, and 24.
Time frame: Up to 24 weeks
Change from Baseline in Coagulation Parameters
Change from baseline in coagulation parameters including international normalized ratio (INR), activated partial thromboplastin time (APTT, seconds), prothrombin time (PT, seconds), and fibrinogen (g/L). Assessed at baseline and Weeks 1, 2, 4, 8, 12, 16, 20, and 24.
Time frame: Up to 24 weeks
Change from Baseline in ECG Parameter: QTcF Interval
Change from baseline in the QT interval corrected for heart rate using Fridericia's formula (QTcF). Measured in milliseconds (ms). Assessed at baseline and Weeks 1, 4, 8, 12, 16, 20, and 24.
Time frame: Up to 24 weeks
Proportion of Participants with CD4⁺ T Cell Count Increase ≥100 cells/μL from Baseline
Proportion of participants achieving an increase from baseline in CD4⁺ T cell count of at least 100 cells/μL. Assessed at baseline and Weeks 4, 8, 12, 16, 20, and 24.
Time frame: Up to 24 weeks
Proportion of Participants Achieving CD4⁺ T Cell Count ≥500 cells/μL
Proportion of participants with CD4⁺ T cell count reaching 500 cells/μL or higher. Assessed at Weeks 4, 8, 12, 16, 20, and 24.
Time frame: Up to 24 weeks
Proportion of Participants with Average CD4⁺ T Cell Count Increase ≥100 cells/μL over 12 Weeks
Proportion of participants with average increase from baseline in CD4⁺ T cell count of at least 100 cells/μL over the first 12 weeks. Assessed from baseline through Week 12.
Time frame: Baseline through Week 12
Proportion of Participants with Average CD4⁺ T Cell Count ≥500 cells/μL over 12 Weeks
Proportion of participants with average CD4⁺ T cell count of 500 cells/μL or higher over the first 12 weeks. Assessed from baseline through Week 12.
Time frame: Baseline through Week 12
Proportion of Participants with Average CD4⁺ T Cell Count Increase ≥100 cells/μL over 24 Weeks
Proportion of participants with average increase from baseline in CD4⁺ T cell count of at least 100 cells/μL over the 24-week study period. Assessed from baseline through Week 24.
Time frame: Baseline through Week 24
Proportion of Participants with Average CD4⁺ T Cell Count ≥500 cells/μL over 24 Weeks
Proportion of participants with average CD4⁺ T cell count of 500 cells/μL or higher over the 24-week study period. Assessed from baseline through Week 24.
Time frame: Baseline through Week 24
Change from Baseline in CD4/CD8 T Cell Ratio
Change from baseline in the ratio of CD4⁺ to CD8⁺ T cells. Assessed at baseline and Weeks 4, 8, 12, 16, 20, and 24.
Time frame: Up to 24 weeks
Proportion of Participants with HIV-1 RNA <50 copies/mL
Proportion of participants maintaining HIV-1 RNA below 50 copies/mL. Assessed at Weeks 4, 8, 12, 16, 20, and 24.
Time frame: Up to 24 weeks
Number of Participants with Clinical Events
Number of participants experiencing clinical events including opportunistic infections, malignancies, and non-AIDS complications (e.g., cardiovascular, renal, hepatic events). Assessed from first dose up to Week 24.
Time frame: Up to 24 weeks
Change from Baseline in Serum Cytokine Levels (IL-2, IL-4, IL-6, IL-8, IL-10, TNF-α, IFN-γ)
Change from baseline in serum levels of cytokines. All measured in pg/mL. Assessed at baseline, Days 1, 2, 3, 5, 8, 15, 22, 23, 24, 26, 29, and Weeks 8, 12, 16, 20, 24.
Time frame: Up to 24 weeks
Change from Baseline in Lymphocyte Subset Counts (cells/μL)
Change from baseline in absolute counts of lymphocytes, T cells (CD3⁺), CD8⁺ T cells, B cells (CD19⁺), natural killer cells (CD56⁺), and their subsets including memory, naive, regulatory, and activation markers (CD38⁺, HLA-DR⁺, PD-1⁺). Assessed at baseline, Days 1, 2, 3, 5, 8, 15, 22, 23, 24, 26, 29, and Weeks 8, 12, 16, 20, 24.
Time frame: Up to 24 weeks
Peak Plasma Concentration (Cmax) - Single Dose
Maximum observed plasma concentration following the first dose. Derived directly from the concentration-time data. Measured in pg/mL. Assessed at pre-dose and at 1, 2, 4, 8, 12, 24, 48, 96, and 168 hours post-dose.
Time frame: Up to 168 hours after first dose
Time to Reach Peak Plasma Concentration (Tmax) - Single Dose
Time to reach maximum observed plasma concentration following the first dose. Measured in hours (h). Assessed at pre-dose and at 1, 2, 4, 8, 12, 24, 48, 96, and 168 hours post-dose.
Time frame: Up to 168 hours after first dose
Elimination Half-Life (t½) - Single Dose
Elimination half-life following the first dose. Calculated as ln(2)/λz, where λz is the terminal elimination rate constant. Measured in hours (h). Assessed at pre-dose and at 1, 2, 4, 8, 12, 24, 48, 96, and 168 hours post-dose.
Time frame: Up to 168 hours after first dose
Area Under the Curve from Time 0 to Last Measurable Concentration (AUC0-last) - Single Dose
Area under the plasma concentration-time curve from time 0 to the time of the last measurable concentration following the first dose. Calculated using the linear trapezoidal rule. Measured in h·pg/mL. Assessed at pre-dose and at 1, 2, 4, 8, 12, 24, 48, 96, and 168 hours post-dose.
Time frame: Up to 168 hours after first dose
Area Under the Curve from Time 0 to Infinity (AUC0-inf) - Single Dose
Area under the plasma concentration-time curve from time 0 extrapolated to infinity following the first dose. Calculated as AUC0-last + Clast/λz. Measured in h·pg/mL. Assessed at pre-dose and at 1, 2, 4, 8, 12, 24, 48, 96, and 168 hours post-dose.
Time frame: Up to 168 hours after first dose
Area Under the Curve from Time 0 to 168 Hours (AUC0-168h) - Single Dose
Area under the plasma concentration-time curve from time 0 to 168 hours following the first dose. Measured in h·pg/mL. Assessed at pre-dose and at 1, 2, 4, 8, 12, 24, 48, 96, and 168 hours post-dose.
Time frame: Up to 168 hours after first dose
Apparent Clearance (CL/F) - Single Dose
Apparent total clearance of the drug from plasma following extravascular administration. Calculated as Dose / AUC0-inf. Measured in L/h. Assessed at pre-dose and at 1, 2, 4, 8, 12, 24, 48, 96, and 168 hours post-dose.
Time frame: Up to 168 hours after first dose
Apparent Volume of Distribution (Vz/F) - Single Dose
Apparent volume of distribution during the terminal phase following extravascular administration. Calculated as Dose / (λz \* AUC0-inf). Measured in L. Assessed at pre-dose and at 1, 2, 4, 8, 12, 24, 48, 96, and 168 hours post-dose.
Time frame: Up to 168 hours after first dose
Steady-State Peak Plasma Concentration (Cmax, ss)
Maximum observed plasma concentration at steady state following the fourth dose (Week 4). Measured in pg/mL. Assessed at pre-dose and at 1, 2, 4, 8, 12, 24, 48, 96, and 168 hours after the fourth dose.
Time frame: Up to 168 hours after the fourth dose (Week 4)
Steady-State Time to Reach Peak Plasma Concentration (Tmax, ss)
Time to reach maximum observed plasma concentration at steady state following the fourth dose. Measured in hours (h). Assessed at pre-dose and at 1, 2, 4, 8, 12, 24, 48, 96, and 168 hours after the fourth dose.
Time frame: Up to 168 hours after the fourth dose (Week 4)
Steady-State Minimum Plasma Concentration (Cmin, ss)
Minimum observed plasma concentration at steady state following the fourth dose. Measured in pg/mL. Assessed at pre-dose and at 1, 2, 4, 8, 12, 24, 48, 96, and 168 hours after the fourth dose.
Time frame: Up to 168 hours after the fourth dose (Week 4)
Steady-State Average Plasma Concentration (Cavg, ss)
Average plasma concentration at steady state over the dosing interval. Calculated as AUC0-tau / τ. Measured in pg/mL. Assessed at pre-dose and at 1, 2, 4, 8, 12, 24, 48, 96, and 168 hours after the fourth dose.
Time frame: Up to 168 hours after the fourth dose (Week 4)
Area Under the Curve Over Dosing Interval (AUC0-tau) - Steady State
Area under the plasma concentration-time curve over the dosing interval (168 hours) at steady state. Measured in h·pg/mL. Assessed at pre-dose and at 1, 2, 4, 8, 12, 24, 48, 96, and 168 hours after the fourth dose.
Time frame: Up to 168 hours after the fourth dose (Week 4)
Steady-State Area Under the Curve from Time 0 to Infinity (AUC0-inf, ss)
Area under the plasma concentration-time curve from time 0 extrapolated to infinity at steady state. Measured in h·pg/mL. Assessed at pre-dose and at 1, 2, 4, 8, 12, 24, 48, 96, and 168 hours after the fourth dose.
Time frame: Up to 168 hours after the fourth dose (Week 4)
Steady-State Apparent Clearance (CLss/F)
Apparent total clearance at steady state. Calculated as Dose / AUC0-tau. Measured in L/h. Assessed at pre-dose and at 1, 2, 4, 8, 12, 24, 48, 96, and 168 hours after the fourth dose.
Time frame: Up to 168 hours after the fourth dose (Week 4)
Steady-State Apparent Volume of Distribution (Vss/F)
Apparent volume of distribution at steady state. Measured in L. Assessed at pre-dose and at 1, 2, 4, 8, 12, 24, 48, 96, and 168 hours after the fourth dose.
Time frame: Up to 168 hours after the fourth dose (Week 4)
Steady-State Elimination Half-Life (t½, ss)
Elimination half-life at steady state. Measured in hours (h). Assessed at pre-dose and at 1, 2, 4, 8, 12, 24, 48, 96, and 168 hours after the fourth dose.
Time frame: Up to 168 hours after the fourth dose (Week 4)
Degree of Fluctuation (DF) - Steady State
Degree of fluctuation at steady state. Calculated as (Cmax, ss - Cmin, ss) / Cavg, ss. No units. Assessed at pre-dose and at 1, 2, 4, 8, 12, 24, 48, 96, and 168 hours after the fourth dose.
Time frame: Up to 168 hours after the fourth dose (Week 4)
Accumulation Ratio for Cmax (RacCmax)
Accumulation ratio for peak concentration. Calculated as Cmax, ss / Cmax following first dose. No units. Assessed after first dose and after fourth dose (Week 4).
Time frame: From first dose to steady state (Week 4)
Accumulation Ratio for AUC (RacAUC0-tau)
Accumulation ratio for area under the curve. Calculated as AUC0-tau, ss / AUC0-tau following first dose. No units. Assessed after first dose and after fourth dose (Week 4).
Time frame: From first dose to steady state (Week 4)
Number of Participants with Anti-Drug Antibodies (ADA)
Number and percentage of participants who develop anti-drug antibodies (ADA) against JL18008. For ADA-positive participants, titers and neutralizing antibody (Nab) status will be assessed. Assessed at baseline, Days 8, 15, 22, 29, and Weeks 8, 12, 16, 20, 24.
Time frame: Up to 24 weeks
Plan to share: No — No individual participant data will be shared. The trial data is proprietary and part of a product development program. Data sharing is not planned at this stage of clinical development.
No publications or documents are linked to this record.
Started May 2026 (actual). Primary completion is estimated for Feb 2027, 8 months after the start.
Of 42 phase 1/2 interventional studies under HIV Infections, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 73. This study's planned 8 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Jecho Biopharmaceuticals Co., Ltd. →